NRAS and melanoma: The efficacy of extracellular signal-regulated kinase kinase inhibitors in NRAS-mutated advanced melanoma has been reported recently (36, 37), and a favorable response to ICI therapy in NRAS-mutated melanoma (38) has also been reported, suggesting the potential role of NRAS mutations as a novel therapeutic target in HNMM.